When to Stop

• Allergic reactions in users with legume / peanut / chickpea / lentil allergy. Fenugreek is in the *Fabaceae* family. Cross-reactivity is well-documented with peanut allergy especially — including anaphylaxis case reports. Anyone with known severe peanut allergy should not use fenugreek without allergist consultation. Severe asthma + fenugreek may also be a high-risk pairing per case reports.
• Acute liver injury — extremely rare, but published case reports exist:
• A postpartum woman taking fenugreek 8 weeks for lactation presented with AST/ALT peak 5720/2164 (PMID-adjacent; SHM abstracts 2017). Recovered without intervention after stopping.
• 2025 case report of a breast-cancer patient on ribociclib (CDK4/6 inhibitor) developing transaminitis attributed to a probable ribociclib-fenugreek herb-drug interaction (Sage 2025). Resolution after discontinuation of both.
• LiverTox official position: fenugreek "has not been implicated in cases of clinically apparent liver injury, and in prospective studies has had no effect on serum enzyme levels." Idiosyncratic case reports exist but are rare. Don't ignore them, but interpret as low-probability tail risk, not a base-rate concern.
• Bleeding / coagulation risk in users on warfarin or DOACs. Fenugreek has documented anti-platelet activity and can prolong bleeding time. Case reports of unexpected INR rises and bruising. Do not co-administer with warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel, or high-dose aspirin without medical oversight.
• Hypoglycemia in diabetic patients on insulin or sulfonylureas. The 4-HO-Ile and galactomannan effects are additive with these drugs. Cases of clinically significant hypoglycemia documented. Monitor glucose if starting fenugreek while on diabetes meds.
• Uterotonic effect / pregnancy harm:
• Fenugreek has documented uterine-stimulating activity in animal studies and is traditionally used in some cultures as a labor-induction agent.
• Animal studies have shown teratogenic + congenital-defect signals at high doses (PMID 11532065 reports pseudo-MSUD in newborns of fenugreek-consuming mothers, plus mechanistic teratology data exists).
• Hard contraindication in pregnancy.
• Theoretical sulfa-drug cross-reactivity discussed in some older literature based on shared structural features. Not strongly supported in modern allergy literature, but worth noting for patients with severe sulfonamide hypersensitivity who want belt-and-suspenders caution.
• Specific watch periods:
• Weeks 1-2: GI adjustment; allergy reactions (if going to happen, usually within first 1-3 doses)
• Weeks 4-8: Bloodwork checkpoint — if running T-protocol, this is when measurable change should appear; if no change, consider stopping vs. dose-doubling
• First 2 weeks of co-use with anticoagulants: monitor INR / bruising (best to just not combine)